Showing 861 - 880 results of 105,092 for search '(( a fold decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.34s Refine Results
  1. 861
  2. 862
  3. 863
  4. 864
  5. 865
  6. 866
  7. 867
  8. 868

    Immunoblotting for TGF-beta, alpha-actinin, MMP-13, and mTOR. by Dwight D. Harris (14484648)

    Published 2024
    “…There was a significant decrease in the ratio of pmTOR to mTOR. …”
  9. 869

    Immunoblotting for JAK, STAT, and SMAD. by Dwight D. Harris (14484648)

    Published 2024
    “…There was also a significant decrease in SMAD and pSMAD in the SIT group. …”
  10. 870
  11. 871

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  12. 872
  13. 873

    Immunoblotting for insulin sensitivity markers. by Dwight D. Harris (14484648)

    Published 2024
    “…There was also a significant decrease in pPKC alpha in the SIT-I myocardium compared to SIT-N. …”
  14. 874
  15. 875
  16. 876
  17. 877
  18. 878

    Blocking of MC1R, MC2R or MC5R causes a decrease in the enucleation ratio of erythrocytes. by Eriko Simamura (720229)

    Published 2015
    “…The enucleation ratio was decreased in the erythroblasts treated with anti-MC1R nAb, anti-MC2R nAb or anti-MC5R nAb. *, <i>P <</i> 0.0001, each point versus control. n = 3; error bars, s.e.m. …”
  19. 879
  20. 880